Collectively, CAR-T targeting CD19 appeared to be effective approach to treat double-refractory CLL to both BTK and BCL-2 inhibitors, particularly with the combination with ibrutinib. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.